Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. expanded its Board of Directors from ten to eleven members and appointed Eric Rubin as a Class I director, effective March 26, 2026. His initial term runs until the 2028 annual meeting of stockholders, and the Board has deemed him an independent director under Nasdaq standards.
Dr. Rubin will serve on the Board’s Nominating, Corporate Governance and Compliance Committee and receive cash and equity pay consistent with other non-employee directors under Natera’s Amended Compensation Program for Non-Employee Directors. His initial equity award will vest in three equal installments on March 26, 2027, 2028 and 2029.
The company also entered into an Indemnification Agreement with Dr. Rubin, providing indemnification and advancement of expenses to the fullest extent permitted by law for claims related to his service. There are no family relationships or related-party transactions requiring disclosure in connection with his appointment.
Solomon Moshkevich filed a Form 144 notice indicating planned sales of 3,000 Performance Shares dated 01/14/2026. The filing lists multiple completed common‑share transactions by the same reporting person during early 2026, including a 23,205‑share sale on 01/20/2026 for $5,447,104.57.
Natera Inc — Schedule 13G/A (Amendment No. 7): The Vanguard Group reports no beneficial ownership. The filing states 0 shares beneficially owned, representing 0% of the class as disclosed in the amendment. The filing explains an internal realignment effective January 12, 2026, causing separate reporting by certain Vanguard subsidiaries.
Natera, Inc. director and co-founder Jonathan Sheena reported open-market sales totaling 4,570 shares of common stock. On March 18 and March 20, 2026, shares were sold at prices generally around $196 to $201 per share through multiple transactions.
A portion of the sales was made from direct holdings, leaving 259,255 shares held directly afterward. Additional sales were conducted by Caraluna 1 Trust and Caraluna 2 Trust, which together held 21,032 shares each after the transactions, and are described as held for the benefit of trust beneficiaries, with Sheena disclaiming beneficial ownership.
Footnotes state that the sales were executed under pre-arranged Rule 10b5-1 trading plans adopted on June 7, 2024 and December 11, 2024, indicating the timing was set in advance.
NTRA reports proposed sales of Common shares under a Form 144 filing, showing multiple dispositions by an affiliate. The filing lists transactions by Jonathan Sheena, including sales of 2,981 shares on 01/20/2026 for $699,755.00, 3,070 shares on 03/02/2026 for $614,710.00, and 3,070 shares on 03/18/2026 for $608,370.00.
The entries show individual sale dates, share counts, and gross proceeds; they record routine reported dispositions rather than company actions. The broker/transfer line shows Charles Schwab & Co., Inc. as the clearing broker in the excerpt.
Jonathan Sheena submitted a Rule 144 notice proposing sales of Common stock previously acquired. The filing lists multiple disposition dates and share amounts as examples, including 3,163 shares on 01/21/2026 and 3,070 shares on 03/02/2026. The sales were processed through Charles Schwab & Co., Inc.
Natera, Inc. director Rowan E. Chapman sold 122 shares of Common Stock in an open-market transaction at $191.38 per share. The sale occurred on March 13, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025.
Following this sale, Chapman directly holds 5,752 Natera shares, indicating that the transaction covers only a small portion of his reported stake.
Natera, Inc. executive chairman Matthew Rabinowitz exercised stock options to acquire 200,000 shares of common stock at an exercise price of $9.59 per share, then sold 200,000 shares in multiple open-market transactions. The sales were executed at weighted average prices generally between about $186 and $198 per share.
According to the filing, all sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2025. After these transactions, Rabinowitz directly holds 2,310,772 shares of Natera common stock, with an additional 5,000 shares held indirectly by his spouse.